Levi Garraway, MD, PhD, recent recipient of the NIH Director’s New Innovator Award and assistant professor of medicine at the Harvard Medical School, has been credited with major advances in cancer biology. Dr. Garraway joins host Dr. Gary Kohn to discuss several common myths within our understanding of cancer biology and therapy.
Cancer is Common (And Other Cancer Myths)
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Overview
Recommended
Details
Presenters
Overview
Levi Garraway, MD, PhD, recent recipient of the NIH Director’s New Innovator Award and assistant professor of medicine at the Harvard Medical School, has been credited with major advances in cancer biology. Dr. Garraway joins host Dr. Gary Kohn to discuss several common myths within our understanding of cancer biology and therapy.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
CME/CE Broadcast Replay
Love Story: Lipid Education for Women’s Heart Health
0.50 credits
<p>Love Story: Lipid Education for Women’s Heart Health</p>
CME/CE
Best Practices for Identifying, Diagnosing and Treating Transthyretin Amyloidosis (ATTR-PN and ATTR-CM)
0.50 credits
<p>Best Practices for Identifying, Diagnosing and Treating Transthyretin Amyloidosis (ATTR-PN and ATTR-CM)</p>
MinuteCE®
HF Management for Patients with Comorbid Conditions
0.75 credits
<p>HF Management for Patients with Comorbid Conditions</p>
MinuteCE®
Level Up Your Skills: Tailoring Management of HF
0.75 credits
<p>Level Up Your Skills: Tailoring Management of HF</p>
MinuteCE®
Clinical Conundrums in ARIA: Communicating ARIA Risk with Patients Considering Anti-Aβ Therapy
1.25 credits
<p>Clinical Conundrums in ARIA: Communicating ARIA Risk with Patients Considering Anti-Aβ Therapy</p>
MinuteCE®
What do we know now that could have changed the history of CETP inhibition?: genetics and biology
0.50 credits
<p>What do we know now that could have changed the history of CETP inhibition?: genetics and biology </p>
NeuroFrontiers
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
<p>Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids</p>
Cardiology
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
<p>Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?